Inhibikase Therapeutics Inc (NASDAQ: IKT) on Monday, soared 3.78% from the previous trading day, before settling in for the closing price of $3.44. Within the past 52 weeks, IKT’s price has moved between $1.12 and $3.82.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 49.79% over the past five years. The company achieved an average annual earnings per share of 74.70%. With a float of $51.26 million, this company’s outstanding shares have now reached $67.19 million.
Let’s look at the performance matrix of the company that is accounted for 8 employees. In terms of profitability, gross margin is -1970400.0%, operating margin of -2006394100.0%, and the pretax margin is -1956524900.0%.
Inhibikase Therapeutics Inc (IKT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Inhibikase Therapeutics Inc is 23.72%, while institutional ownership is 45.27%. The most recent insider transaction that took place on Oct 21 ’24, was worth 2,000,200. In this transaction Director of this company bought 1,460,000 shares at a rate of $1.37, taking the stock ownership to the 1,460,000 shares. Before that another transaction happened on Oct 21 ’24, when Company’s Director bought 145,000 for $1.37, making the entire transaction worth $198,650. This insider now owns 145,000 shares in total.
Inhibikase Therapeutics Inc (IKT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 74.70% per share during the next fiscal year.
Inhibikase Therapeutics Inc (NASDAQ: IKT) Trading Performance Indicators
Inhibikase Therapeutics Inc (IKT) is currently performing well based on its current performance indicators. A quick ratio of 0.74 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.72, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.45 in one year’s time.
Technical Analysis of Inhibikase Therapeutics Inc (IKT)
Inhibikase Therapeutics Inc (NASDAQ: IKT) saw its 5-day average volume 0.46 million, a positive change from its year-to-date volume of 0.2 million. As of the previous 9 days, the stock’s Stochastic %D was 73.69%. Additionally, its Average True Range was 0.37.
During the past 100 days, Inhibikase Therapeutics Inc’s (IKT) raw stochastic average was set at 86.88%, which indicates a significant increase from 77.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 98.75% in the past 14 days, which was higher than the 96.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.44, while its 200-day Moving Average is $1.82. Nevertheless, the first resistance level for the watch stands at $3.82 in the near term. At $4.08, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.21. If the price goes on to break the first support level at $3.43, it is likely to go to the next support level at $3.30. Assuming the price breaks the second support level, the third support level stands at $3.04.
Inhibikase Therapeutics Inc (NASDAQ: IKT) Key Stats
Market capitalization of the company is 254.68 million based on 67,193K outstanding shares. Right now, sales total 260 K and income totals -19,030 K. The company made 0 K in profit during its latest quarter, and -5,780 K in sales during its previous quarter.
